238 related articles for article (PubMed ID: 15723344)
1. Histone modifications as a platform for cancer therapy.
Espino PS; Drobic B; Dunn KL; Davie JR
J Cell Biochem; 2005 Apr; 94(6):1088-102. PubMed ID: 15723344
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
4. Targeting aberrant chromatin structure in colorectal carcinomas.
Konishi K; Issa JP
Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic changes in cancer.
Grønbaek K; Hother C; Jones PA
APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
[TBL] [Abstract][Full Text] [Related]
6. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
7. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
8. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.
Osada H; Tatematsu Y; Sugito N; Horio Y; Takahashi T
Mol Carcinog; 2005 Dec; 44(4):233-41. PubMed ID: 16163707
[TBL] [Abstract][Full Text] [Related]
9. Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its interdigitation with chromatin.
Baylin SB
Novartis Found Symp; 2004; 259():226-33; discussion 234-7, 285-8. PubMed ID: 15171257
[TBL] [Abstract][Full Text] [Related]
10. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Conley BA; Wright JJ; Kummar S
Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
Vaissière T; Sawan C; Herceg Z
Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
13. Targeting histone deacetylase in cancer therapy.
Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
[TBL] [Abstract][Full Text] [Related]
14. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
[TBL] [Abstract][Full Text] [Related]
15. Targeting DNA methylation in cancer.
Szyf M
Bull Cancer; 2006 Sep; 93(9):961-72. PubMed ID: 16980240
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic gene regulation in cancer.
Ballestar E; Esteller M
Adv Genet; 2008; 61():247-67. PubMed ID: 18282509
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
Bhalla KN
J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
[TBL] [Abstract][Full Text] [Related]
18. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
19. Chromatin-remodelling mechanisms in cancer.
Lafon-Hughes L; Di Tomaso MV; Méndez-Acuña L; Martínez-López W
Mutat Res; 2008; 658(3):191-214. PubMed ID: 18403253
[TBL] [Abstract][Full Text] [Related]
20. Talk is cheap--cross-talk in establishment, maintenance, and readout of chromatin modifications.
Fischle W
Genes Dev; 2008 Dec; 22(24):3375-82. PubMed ID: 19141469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]